The medicine in question, Canagliflozin, influences T-cells – cells normally tasked with combating infections, which in autoimmune diseases may mistakenly attack healthy bodily tissue.

Indian drug companies are set to revolutionize diabetes treatment with affordable generic versions of Empagliflozin, following the expiry of its patent. Estimated to significantly cut costs and ...